Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2791868 | Best Practice & Research Clinical Endocrinology & Metabolism | 2008 | 15 Pages |
Abstract
There is now a reasonably good understanding of the key oncogenic events involved in the initiation and progression of thyroid cancer. Many of these are characteristic of certain tumor types, and their presence conveys diagnostic and prognostic information. It is not yet clear how this information will be applied to clinical practice. Based on preclinical evidence, mutations of genes encoding certain kinases may also predict response to specific tyrosine kinase inhibitors, although this has not yet been explored systematically in clinical trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
James A. Fagin, Nicholas Mitsiades,